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Structured Abstract  
Identifying maturity onset diabetes of the young (MODY) in pediatric populations close to 
diabetes diagnosis is difficult. Misdiagnosis and unnecessary insulin treatment are common.  
Objective 
We aimed to identify the discriminatory clinical features at diabetes diagnosis of patients 
with GCK, HNF1A and HNF4A MODY in the pediatric population. 
Research Design and Methods 
Swedish patients (n=3933) aged 1-18 years, diagnosed with diabetes May 2005-December 
2010 were recruited from the national consecutive prospective cohort ‘Better Diabetes 
Diagnosis’ (BDD). Clinical data, islet autoantibodies (GADA, IA-2A, ZnT8A, and IAA), HLA type 
and C-peptide were collected at diagnosis. MODY was identified by sequencing GCK, HNF1A 
and HNF4A, either through routine clinical  or research testing.  
Results 
The minimal prevalence of MODY was 1.2%. Discriminatory factors for MODY at diagnosis 
included 4 islet autoantibody negativity (100%vs11% not known MODY; p=2x10-44), HbA1c 
(7.0vs10.7%, 53vs93 mmol/mol, p=1x10-20), plasma glucose (11.7vs26.7mmol/L, p=3x10-19), 
parental diabetes (63%vs12% p=1x 10-15), and DKA (0/46vs601/3887, p=0.001).  Testing 303 
autoantibody negative patients identified 46 MODY patients (detection rate 15%). Limiting 
testing to the 73 antibody negative patients with HbA1c<7.5%(58mmol/mol) at diagnosis 
identified 36/46(78%) MODY patients (detection rate 49%). On follow-up the 46  MODY 
patients had excellent glycaemic control, HbA1c 6.4% (47mmol/mol) with42/46(91%) not on 
insulin treatment. 
Conclusions  
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At diagnosis of pediatric diabetes absence of all islet autoantibodies and modest 
hyperglycaemia (HbA1c <7.5% (58mmol/mol)) should result in testing for GCK, HNF1A and 
HNF4A MODY.  Testing all 12% patients negative for 4 islet autoantibodies is an effective 
strategy for not missing MODY but will result in a lower detection rate. Identifying MODY 
results in excellent long term glycaemic control without insulin.  
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Maturity onset diabetes of the young (MODY) is a monogenic, dominantly inherited, 
diabetes that is typically diagnosed young but is not insulin dependent.  Recognizing MODY 
is important as treatment and management is different from type 1 diabetes and type 2 
diabetes. Diabetes in children is predominantly type 1 diabetes, but type 2 diabetes and 
MODY also occur (1, 2).  MODY accounts for 1-4% of pediatric diabetes (1, 3-7), but 
misdiagnosis results in many young people being treated unnecessarily with insulin (1,4) 
with many years delay from initial diabetes diagnosis to correct genetic diagnosis (8). 
The commonest subtypes of MODY are Glucokinase (GCK) MODY which needs no treatment 
and Hepatocyte Nuclear Factor 1 alpha (HNF1A) MODY and Hepatocyte Nuclear Factor 4 
alpha (HNF4A) MODY which are both optimally treated with low dose sulphonylureas when 
pharmaceutical therapy is needed (2,9).  
Identifying MODY in pediatric diabetes populations is diagnostically difficult as no single or 
combination of commonly used clinical criteria can adequately separate them from type 1 
diabetes and type 2 diabetes (1,2,10,11).  This is particularly true close to diagnosis, when 
those with type 1 diabetes continue to produce endogenous insulin. Increasing obesity in all 
children (12) can also make differential diagnosis from type 2 diabetes challenging (13).  
Islet autoantibodies can be useful in identifying ‘non type 1 diabetes’ and are rarely detected 
in MODY, being present in only 1% of cases, similar to the healthy population (14). In 
contrast islet autoantibodies are detected in approximately 90% of children with type 1 
diabetes at diagnosis (15,16).  Despite this, use of islet autoantibodies is not universally 
advocated and comprehensive islet autoantibody testing of all 4 sub-types glutamic acid 
decarboxylase (GADA), insulinoma antigen-2 (IA-2A), ZnT8 transporter (ZnT8A) and insulin 
(IAA) is not routinely performed in clinical care.  
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A correct diagnosis of MODY in children and adolescents leads to improved treatment with 
the avoidance of insulin, no deterioration in HbA1c (17, 18) and cost savings (19). Making the 
genetic diagnosis as close as possible to the diabetes diagnosis will reduce delays in starting 
recommended treatment. Approaches to the recognition of MODY are currently 
predominantly based on clinical features at follow-up rather than at diagnosis (20).  
The aim of our study was to identify the discriminatory clinical features of the commonest 
types of MODY at diagnosis of diabetes in a pediatric national cohort. 
 
Research Design and Methods  
Individuals aged between 1-18 years, with a new diagnosis of diabetes were recruited from 
the national consecutive prospective cohort ‘Better Diabetes Diagnosis’ (BDD) study, 
involving 42 hospital pediatric clinics in Sweden, from May 2005 to December 2010 (21). A 
total of 4574 children and young people between the ages of 1-18 years were diagnosed 
with diabetes during the study period and 3933 (86%) were recruited into the study cohort 
(Figure 1).  Participants were 45% female (n=1755) and had a mean age of diagnosis of 10.1 
years.  
Clinical characteristics: Clinical data including symptoms of polyuria, polydipsia and weight 
loss,  family history of diabetes  and samples for plasma glucose concentration, HbA1c, islet 
autoantibodies against GADA, IA-2A, ZnT8A and insulin, HLA type and C-peptide were 
collected at diagnosis.  The routine laboratory tests, plasma-glucose, pH and HbA1c, were 
analysed locally with results returned within 24 hours and   are described as ‘early’ 
investigations (Supplementary Table 1). Diabetic ketoacidosis (DKA) was defined as pH <7.3 
OR serum bicarbonate <15mEq/L with a plasma glucose >11mmol/L. Blood samples sent to 
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the reference laboratory for analyses of all islet autoantibodies (GADA, IA-2A, ZnT8A and 
IAA), HLA genotype and random C-peptide are described as ‘delayed’ as the results were 
returned to the clinician within 14-90 days(Supplementary Table 1). Demographic data, 
symptoms, physical signs and blood analysis at onset were registered in SWEDIABKIDS, a 
national incidence and longitudinal quality control register for children and adolescents with 
diabetes (22).  
Molecular genetic testing was undertaken to identify the commonest causes of MODY (GCK, 
HNF1A and HNF4A), all of which need different treatment from type 1 or type 2 diabetes. 
The molecular genetic sequencing of the whole coding region and critical noncoding regions 
of each gene was either performed as a result of a clinical request or as a research test at the 
diagnostic laboratory at the Royal Devon and Exeter NHS Foundation Trust, Exeter, UK 
(www.diabetesgenes.org) or at the Department of Clinical Chemistry, Division of Laboratory 
Medicine, Skåne University Hospital, Malmö, Sweden. Clinical referrals for genetic testing 
were predominantly requested in autoantibody negative patients 76/81 (94%) (Figure 1). 
 
Of those who were islet autoantibody negative there were a total of 386/462 patients who 
were not tested clinically.  To assess if cases of MODY had been missed that would alter 
treatment, research sequencing of the HNF1A, HNF4A and GCK genes was undertaken in an 
additional 404 patients (227 autoantibody negative  and 177 autoantibody positive). We 
‘research tested’ all 227 autoantibody negative patients in whom there was sufficient DNA 
for genetic sequencing.  There were 159 islet autoantibody negative patients who were not 
tested on a clinical or research basis as there was insufficient DNA available (Figure 1). We 
compared  the characteristics of the 159  islet autoantibody negative patients not research 
tested with   the 227 ‘research tested’ patients (supplementary table 2).    No variables were 
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significant after correction for multiple testing. Therefore, the patients ‘research tested’ 
were representative of the whole group who were islet autoantibody negative and not 
tested clinically. 
To provide a random collection of autoantibody positive patients we identified 250 
consecutive patients. Research sequencing was performed on the 177 of these islet 
autoantibody positive patients that had not been tested clinically where we had adequate 
quantity of DNA for genetic testing.  We compared the characteristics of the randomly 
selected 177 autoantibody positive patients who were ‘research tested’ for MODY to the 
3294 antibody positive patients who were not tested (supplementary table 3). No variables 
except C peptide were significant after correction for multiple testing.  Therefore, the 
patients research tested were representative of the whole group who were islet 
autoantibody positive and not tested clinically. 
 
Details of testing:  
Autoantibodies:  
Autoantibodies against GADA, IA-2A, ZnT8A and IAA were analyzed in radio binding assays 
(23). The cut off values used equated to the level found in only 1% of an age matched 
population (23). GADA and IA-2A levels were expressed as U/ml derived from the WHO 
standard 97/550 and were considered positive if GADA were >35U/ml and IA-2A levels 
>5U/ml. The intra-assay CV for duplicates was 5 % for GADA and 11% for IA-2A.   The radio 
ligand binding assay for all three ZnT8 autoantibodies (ZnT8A) variants (ZnT8RA, ZnT8WA 
and ZnT8QA) were analysed (24). Cut off values for positive results were ZnT8RA ≥75 U/ml, 
ZnT8WA ≥75 U/ml and ZnT8QA ≥ 100 U/ml. The intra-assay CV was 5.5% for ZnT8RA, 5.3% 
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for ZnT8WA, and 4.9% for ZnT8QA, respectively. IAA was considered positive if >0.8 relative 
units (RU). The intra-assay CV in the IAA assay was 6.0% (23).  
The laboratory undertaking the autoantibody analyses participates in the biannual Islet 
Autoantibody Standardization Program (http://www.immunologyofdiabetssociety.com/).  
HLA genotyping  
Dried blood spots (DBS) were used for PCR amplification with sequence-specific 
oligonucleotide probes of HLA-DQB1 and DQA1 alleles using a DELFIA Hybridization assay 
(Perkin Elmer, Boston, MA) (25). The HLA-DQB1* probes defined the presence of HLA-
DQB1*02, 03:02, 03:01, 06:02, 06:03 and 06:04 alleles and the HLA-DQA1 probes the 
DQA1*02:01, 03 and 05 alleles (25-27).  
C-peptide measurement 
Serum C-peptide, from the random non-fasting blood sample, was measured at Linkoping 
University, Sweden, with a time-resolved fluoroimmunoassay (AutoDELFIATM C-peptide kit, 
Wallac, Turku, Finland), with a detection level of 0.03 nmol/L (28).  
Molecular genetic testing for MODY 
The coding exons and conserved splice sites of HNF1A, HNF4A and GCK were amplified by 
PCR and sequenced on an ABI 3730 (Applied Biosystems, Warrington, UK). Sequences were 
compared to the published reference sequences (NM_000545.6 for HNF1A, NM_175914.4 
for HNF4A and NM_000162.5 for GCK) using Mutation Surveyor v3.24 (SoftGenetics, PA, 
USA) or ABI SeqScape Software v2.5 (Applied Biosystems, Warrington, UK). Variants were 
classified according to the American College of Medical Genetics and Genomics guidelines 
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(29). MODY was diagnosed by the identification of heterozygous pathogenic or likely 
pathogenic variants.  
Statistical methods  
For statistical testing of binary variables we used Fisher’s exact test and for continuous traits 
we used unpaired t-tests. Where the continuous traits were not normally distributed we log 
transformed the variable (indicated in tables). All analyses were performed in Stata v14. 
Ethical approval 
The Regional Ethics Board at the Karolinska Institute, Stockholm, Sweden approved the BDD 
study (Dnrs 2004-826/1, 2006/1082-32, 2009/1684-32). 
The study is written in line with STROBE guidelines (https://strobe-statement.org/) for 
cohort studies. 
Results 
 
88% (3471/3933) of patients were positive for at least one islet autoantibody when all 4 
autoantibodies were analyzed (Supplementary Table 1). The characteristics of the 
autoantibody positive and autoantibody negative patients are provided in Supplementary 
Table 1. We examined how testing a lower number of autoantibodies would change the 
number of individuals identified as autoantibody negative (Table 2).  This table shows that 
each additional autoantibody tested result in less autoantibody negative patients being 
identified but with a reducing impact. So the number of autoantibody negative patients is 
49% with GADA testing only, 17% GADA and IA-2A, 13% GADA, IA-2A and ZnT8A and 12% 
 11 
with all 4 autoantibodies.  The detailed breakdown of the distribution of different 
autoantibodies is in Supplementary Figure 1 
MODY was only identified in autoantibody negative patients (Figure 1). There were no 
cases of MODY identified in the autoantibody positive cases tested either clinically (n=5) or 
through research testing of consecutively selected individuals, (n=177) who were positive for 
at least one islet autoantibody (Figure 1).  
The clinical features of those with confirmed MODY (Table 1). The strongest discriminatory 
clinical features of MODY at diagnosis in addition to  being negative to all 4 islet 
autoantibodies (100% vs 11% not known MODY; p=2x10-44) were:  lower HbA1c 7.0 vs 10.7% 
(53 vs 93 mmol/mol, p=1x10-20), lower random plasma glucose (mean 11.7 vs 26.7mmol/L, 
p=3x10-19), parental diabetes  (63% v 12%) p=1x 10-15 and not having DKA (0/46 vs 601/3887, 
p=0.001).  
There was a high detection rate of MODY, 34/76 (45%), in the autoantibody negative 
patients tested on clinician’s request (Figure 1). Clinical molecular genetic diagnosis of 
MODY in these 34 patients was made at a median of 9 (IQR 4-21) months post clinical 
diagnosis of diabetes. The patients clinically tested were more likely to be autoantibody 
negative, had lower plasma glucose and HbA1c and were more likely to have a parent with 
diabetes (Supplementary Table 4).   
There was a lower rate of MODY detection, 12/227 (5%), in the autoantibody negative 
patients who had genetic testing as part of this research and were not referred for genetic 
testing by their clinicians (Figure 1).  
The MODY subtypes identified were: GCK MODY in 29 (63%), HNF1A MODY in 10 (22%) and 
HNF4A MODY in 7 (15%) patients. The distribution of the different MODY types in the 
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autoantibody negative group, not referred for genetic testing by clinicians and tested on a 
research basis, was similar. The specific gene variants identified are shown in Supplementary 
Table 5. 
46/303 (15%) of autoantibody negative patients were found by genetic testing to have 
MODY resulting in a minimal prevalence of 1.2% (46/3933) (Figure 1). If we assume the 
detection rate of 5% MODY in the 159 autoantibody negative patients who were not 
referred clinically nor tested on a research basis (n=159) was similar to the 227 who were 
tested we would expect to find an additional 8 patients with MODY giving an estimated 
prevalence of 1.4% (54/3933) in this pediatric population.  
Autoantibody negativity was by far the strongest discriminatory clinical feature of MODY.  
Patients with MODY, 46/46 (100%), were negative for all 4 autoantibodies compared to just 
416/3887 (11%) subjects not known to have MODY (p<0.0001; Table 1).   
Among the autoantibody negative patients those with MODY had markedly less severe 
hyperglycaemia than those without MODY. HbA1c (7.0 vs 10.2% [53 vs 88mmol/mol]) and 
mean random plasma glucose: (11.7 vs 23.7mmol/L) were less severe in the MODY patients 
(Figure 2 and Supplementary Figure 2). They were less likely to have osmotic symptoms 
(polyuria and polydipsia) and weight loss but more likely to have a parent with diabetes (63 
vs 27%, p=4x10-6) (Supplementary Table 6). In a multiple logistic regression model in this 
autoantibody negative group of all variables that were significant in univariate analysis 
(P<0.05) only plasma glucose (p=6x10-5) and parental history of diabetes (p=0.02) remained 
statistically significant discriminators of MODY.  The characteristics of GCK, HNF1A and 
HNF4A MODY compared to non-MODY patients and to each other are shown in 
supplementary tables 7, 8 and 9.   
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Testing using previously suggested clinical criteria for discriminating MODY:  
In our study genetic testing in 303 patients who were antibody negative detected 46 
patients with MODY which is a detection rate of 15% (46/303).  We went on to test how 2 
previously defined criteria relating to HbA1c and family history altered the detection rate 
and the number of patients detected. See supplementry table 10. We used HbA1c rather 
than plasma glucose even though the latter was slightly more discriminatory as it used in 
previous clincal criteria and is less variable than glucose. 
If testing was limited to the 73 patints who in additon to being antibody negative also had an 
had an HbA1c below the previously defined upper limit of HbA1c 7.5% (58mmol/mol) for the 
diagnosis of GCK MODY (30) this improved the detection rate to 49% (36/73) and identified 
78% (36/46) patients with MODY. These criteria, as expected, were excellent for detecting 
GCK MODY (29/29 patients) but also detected 41% (7/17) of HNF1A and HNF4A MODY 
patients.  
A dominant family history has been a defining feature of MODY (9). If testing was limited to 
patients who were autoantibody negative with a parental family history would result in 
testing 96 people with a detection rate of 30% (29/96) and would detect 63% (29/46) 
patients with similar proportions in GCK (18/29) and HNF1A/4A (11/17) MODY. 
If those with HbA1c <7.5% (58mmol/mol) OR  an affected parent were tested (n=131) then 
the detection rate was 33% (44/131) with 44/46 (96%) of MODY cases detected 
(supplementary table 10).  
Therefore both glycaemia at diagnosis and family history have a role in selecting which 
autoantibody negative patients to test but if selecting on a single clinical criteria only then 
HbA1c <7.5%  (58mmol/mol) is both more sensitive and more specific than family history.   
 14 
 
Patients identified with a genetic diagnosis of MODY had an excellent outcome.  
At a mean of 5.9 years after initial diabetes diagnosis excellent glycaemic control was 
achieved in all individuals with a genetic diagnosis of MODY with mean (SD) HbA1c 6.4 
(1.0)% (47 (8) mmol/mol).  A total of 42/46 (91%) patients were not on insulin and were on 
recommended treatment: no treatment for GCK MODY (29/29, 100%), diet or sulphonylurea 
for HNF1A MODY (9/10, 90%) and HNF4A MODY (4/7, 57%). 14/18 patients, started on 
insulin at initial diabetes diagnosis, had discontinued insulin treatment following a positive 
genetic test (Supplementary Table 11).  
 
Conclusions  
This is the first large prospective national study to examine all clinical features at diagnosis of 
diabetes. Our study provides clear support for identifying pediatric patients for MODY 
testing by excluding type 1 diabetes through high quality, comprehensive autoantibody 
testing using 4 autoantibodies. In the autoantibody negative patients the most 
discriminatory clinical features are low glycaemia (plasma glucose or HbA1c) and family 
history.  Our study suggests that testing autoantibody negative patients with HbA1c <7.5% 
(<58mmol/mol) will identify over ¾ of GCK, HNF1A and HNF4A MODY with a detection rate 
of approximately 50%”..  
The minimal incidence of MODY in patients aged 1-18 years identified in this Swedish cohort 
was 1.2% and the estimated prevalence, if all autoantibody negative patients had been 
tested in this cohort would be 1.4%. The prevalence seen in other studies of pediatric 
diabetes have been reported as follows: Norway (0.5%) (3), USA (1.2%) (1), Italy (1.6%) or 
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6.3% including incidental hyperglycaemia (5), Australia 1.9% (6), UK (2.5%) (4) and Poland 
(3.1-4.2%) (7).  However our study included a better coverage of the population (86% of all 
newly diagnosed cases of pediatric diabetes) and our data was collected prospectively, as 
opposed to a cross-sectional or selected cohort.  
Autoantibody negativity was a key feature of those identified with MODY. This finding was 
similar to previous studies but within our study autoantibody testing was comprehensive, 
with four autoantibodies tested and was also performed at diagnosis. This approach 
efficiently leads to more type 1 diabetes patients being positively identified and reduces the 
number of cases needing consideration for MODY testing. The fact that our cohort was 
recruited at diagnosis means that a low (< 200pmol/l) C-peptide result was not found in the 
majority of patients with antibody positive Type 1 diabetes. C-peptide testing was used in 
both US and UK studies (1, 4) but both recruited patients who were usually many years after 
the initial diabetes diagnosis.   
Our study indicates that very few cases of MODY will be missed if genetic testing is limited to 
children who are negative for all 4 autoantibodies. As 1% of the normal population are islet 
autoantibody positive at the levels used as cut offs, then 1% of MODY patients can also be 
expected to have autoantibodies. However, as MODY is rare and type 1 diabetes is common 
in pediatric diabetes populations and approximately 90% type 1 diabetes children are 
autoantibody positive close to diagnosis the number of patients with MODY predicted in the 
autoantibody positive patients would be <0.1%. Therefore we consider data from this and 
other studies means autoantibody positivity is a reasonable exclusion for progressing to 
genetic testing in a person with diabetes in the pediatric age range (14, 31).   
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The breakdown of autoantibody positivity indicates that there is a clear benefit for testing 3 
islet autoantibodies (GADA, IA-2A and ZnT8A). However only few additional patients will be 
found to be positive if IAA testing is also  performed at diagnosis.  The additional technical 
difficulty of testing IAA only reduces the number that are autoantibody negative from 13% of 
pediatric diabetes to 12% and may not be considered necessary clinically.  
In our study the results of the autoantibody tests were returned to all clinicians and this was 
a major determinant of which patients the clinicians referred for genetic testing. This led to a 
very high rate of detection of MODY (45%) compared to 27% in reported routine services (8).  
This is the first study performed at the time of diabetes diagnosis. Samples and data were 
typically collected at diagnosis before insulin was given. The US SEARCH study included 
patients close to diagnosis but was typically around eight months post initial diabetes 
presentation (1). Our study enabled accurate recording of initial symptoms and acute 
investigations at diagnosis of diabetes. The key features of those with MODY that we 
identified at diabetes diagnosis included, lower HbA1c,  lower plasma glucose and less 
osmotic symptoms which all reflect less severe hyperglycaemia and there were no patients 
with MODY who presented in ketoacidosis.   
A key issue is what is the appropriate level of sensitivity and specificity of the threshold set 
for systematic testing of patients. The low prevalence of MODY means that even features 
with a very high odds ratio have a low positive predictive value. This makes it hard to identify 
likely cases and unduly strict criteria while resulting in a high detection rate but will miss 
cases. With a reduction in the cost of genetic testing it may be the most effective strategy to 
sequence all pediatric patients with diabetes who are negative on testing four 
autoantibodies, leading to a detection rate of 15%. Our results support that pre-specified 
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cut offs of HbA1c <7.5% in antibody negative patients gives a much higher detection rate for 
the person being tested having MODY (50%) of but would miss 2% of cases (mainly HNF1A 
and HNF4A MODY ). A compromise might be to test all antibody negative patientswith an 
HbA1c < 7.5% or a parent with diabetes; this approach had an detection rate  33%  and 
detected 94% MODY.     
It is interesting that, after receiving the islet autoantibody results, clinicians chose to test 
only 76/462 (16%) of the autoantibody negative patients but had a high detection rate 34/76 
(45%) in those they did test. The main factors that influenced clinician testing were severity 
of glycaemia and family history (supplementary table 12). Ultimately a model that integrates 
all clinical factors may outperform clinician choice but at present either testing all islet 
autoantibody negative patients or those with a predefined HbA1c cut off of <7.5% at 
diagnosis performs better than clinician choice with less MODY cases missed.  
It is important to detect MODY as our results show improved outcome both in terms of 
insulin cessation and HbA1c. This study has prospectively has followed-up the impact of a 
diagnosis of MODY from diabetes diagnosis to effect on clinical outcomes, 42/46 (91%) were 
not on insulin at follow up, 14/18 of these had ceased insulin treatment (which had been 
started at initial diabetes diagnosis) and excellent glycaemic control was achieved, HbA1c 
mean (SD) 6.4 (1.0)% (47 (8) mmol/mol) (Supplementary table 11). 2/4 of the individuals still 
on insulin chose to remain on this treatment. Stopping insulin can be a major challenge for 
some patients and this highlights the importance of identifying the correct genetic diagnosis 
as soon as possible (32). 
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The major strengths of this study is that it is a large,  consecutive series recruiting 86% of 
cases of newly diagnosed diabetes in the pediatric population at diagnosis allowing 
assessment of both clincal features and antibodies at diagnosis.  
It is also a strength that all autoantibody tests were carried out for the entire country at a 
central BDD laboratory at the Lund University CRC at Skåne University Hospital in Malmö. 
The laboratory is participating in the Islet Autoantibody Standardization program and has 
very good results. In addition, all samples are subjected to end point titration to better 
define cut off levels compared to a large number of serum and plasma samples from healthy 
individuals. All three isoforms of ZnT8A (R, W or Q at position 325) were analyzed to ensure 
that children single positive for any of the three variants were accounted for (15, 23). 
However most commonly clincally used ELISA assays for ZnT8A will detect as positive > 99% 
of samples positve for the 3 separate isoforms as they detect the common R and W variants. 
Only pathogenic or likely pathogenic variants have been included in this study 
(Supplementary table 3). The only likely pathogenic variants are in GCK, and so further 
investigations could be performed by testing other family members to check for segregation 
of the variant with fasting hyperglycaemia and raised HbA1c.  Variants of uncertain 
significance were not included since they cannot be used to diagnose MODY. 
A weakness of this study is that only the three commonest subtypes of MODY, that can alter 
treatment, were tested. If a next generation sequencing approach is used in children 
allowing testing of all potential monogenic subtypes cases then there is a slight increase 
(approximately 15%) more monogenic diabetes cases than the common GCK, HNF1A and 
HNF4A MODY cases alone) (4). The data presented applies to the Swedish population and 
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will vary in other populations especially when there is a higher representation of ethnic 
groups with a lower prevalence of Type 1 diabetes in the population.  
In conclusion at diagnosis of pediatric diabetes comprehensive autoantibody testing and 
degree of glycaemia are key clinical features of MODY allowing differentiation from type 1 
diabetes. Establishing negativity to four islet autoantibodies at diabetes diagnosis in the 
pediatric population efficiently identifies which individuals should be considered for genetic 
testing. Within the autoantibody negative patients modest hyperglycaemia, indicated by an 
HbA1 <58mmol/mol (<7.5%), and family history are further features that can be used to 
guide testing. Identifying patients for genetic testing at diabetes diagnosis will prevent 
delays in the correct molecular genetic diagnosis of patients. This will lead to improvements 
in treatment, quality of life and reductions in treatment and monitoring costs and should be 
universally advocated in pediatric diabetes patients at diagnosis. 
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Table 1: Clinical features and investigation results of MODY (HNF1A, HNF4A and GCK) and 
Not known MODY patients.  
^ Not known MODY consist of n=3471 autoantibody positive (182 MODY tested) and 416 
antibody negative  (257 MODY tested). 
Plasma glucose and C peptide results based on log10 transformation. 
*early local testing with results 0-24 hours   
†testing at reference laboratories where results were delayed (14-90 days) 
 
  
 HNF1A/HNF4A/ 
GCK MODY 
(n=46) 
Not known MODY 
(n=3887)^ 
Phenotype N mean (SD) 
or % (N) 
N mean (SD) 
or % (N) 
P  
      
Clinical features      
N 46  3887   
Sex (% female) 46 54 (25) 3887 45 (1730) 0.23 
Age at diagnosis (yrs) 46 12.1 (4.4) 3887 10.1 (4.4) 3x10-3 
Parental Diabetes (%) 46 63 (29) 3887 12 (471) 1x10-15 
Polyuria (%) 38 34 (13) 3570 95 (3378) 2x10-22 
Polydipsia (%) 38 34 (13) 3559 94 (3350) 2x10-21 
Weight loss (%) 38 16 (6) 3449 76 (2619) 1x10-14 
BMI (SDS) 37 0.54 (1.2) 3341 -0.36 (1.6) 7x10-4 
Acanthosis Nigricans (%) 37 0 (0)  3453 100 (44) 1 
      
Investigations- early*      
Plasma glucose (mmol/L) 41 11.7 (4.1) 3528 26.7 (9.0) 3x10-19 
HbA1c (%) 46 7.0 (3.7) 3495 10.7 (4.5) 1x10-20 
DKA (%) 46 0 (0) 3887 15 (601) 0.001 
      
Investigations – delayed†      
4 Autoantibody negative 
(%) 
46 100 (46) 3887 11 (416) 2x10-44 
High risk HLA (%) 46 20 (9) 3830 70 (2684)  3x10-12 
C peptide (nmol/mol) 41 0.99 (0.63) 3555 0.34 (0.43) 1x10-14 
C Peptide <0.2 (nmol/mol) 41 2 (1) 3555 40 (1433) 4x10-8 
 25 
Number of 
autoantibodies 
tested 
Autoantibody positive to: N positive 
(%)     
(/3933) 
N (%) of people who tested 
negative with this testing of 
antibody combination 
1 antibody  GAD 2081 (53) 1852 (47) 
IA2 2718 (69) 1215 (31) 
2 antibodies GAD and/or IA2 3263 (83) 670 (17) 
3 antibodies GAD and/or IA2 and /or ZnT8 3428 (87) 505 (13) 
4 antibodies GAD and/or IA2 and/or ZnT8 
and/or IAA 
3471 (88) 462 (12) 
 
 
 
 
Table 2: Combinations of commonly tested autoantibodies, illustrating number and 
percentage of individuals positive to at least one autoantibody and percentage of patients 
negative depending on combination tested. 
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Figure 1. Study flow diagram: MODY was only identified in islet autoantibody negative 
patients 
 
 
 
Figure 2.  MODY patients had lower HbA1c at diagnosis than those without MODY.  
Data shown as a Box and Whisker plot: the ends of the box are the upper and lower 
quartiles, the median is marked as the vertical line inside the box. The vertical lines indicate 
the maximum and minimum values excluding extreme outliers shown as dots.  HbA1c of 
7.5% (58mmol/mol) cut off for GCK MODY (ref 30) shown as red dotted line. 
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Supplementary Table 1. Clinical characteristics of subjects. Plasma glucose and C peptide 
results based on log10 transformation. 
 * local testing with results 0-24 hours  
† testing at reference laboratory, results within 14-90 days 
 
  
 All Patients Autoantibody +ve Autoantibody -ve  
Phenotype N mean (SD) 
or % (N) 
N mean (SD) 
or % (N) 
N mean (SD) 
or % (N) 
P 
Clinical features        
N   3471  462   
Sex (% female) 3933 45 (1755) 3471 45 (1566) 462 41 (189) 0.09 
Age at diagnosis (yrs) 3933 10.1 (4.4) 3471 9.9 (4.4) 462 11.6 (4.5) 5x10-14 
Parental Diabetes (%) 3933 13 (500) 3471 11 (379) 462 26 (121) 4x10-17 
Polyuria (%) 3608 94 (3392) 3233 96 (3104) 375 77 (288) 2x10-33 
Polydipsia (%) 3597 93 (3363) 3225 95 (3077) 372 77 (286) 1x10-29 
Weight loss (%) 3487 75 (2625) 3129 77 (2423) 358 56 (202) 2x10-16 
BMI (SDS) 3378 -0.35 (1.55) 3020 -0.44 (1.49) 358 0.43 (1.83) 1x10-16 
Acanthosis Nigricans 
(%) 
3490 1 (44) 3136 1 (17) 354 8 (27) 8x10-17 
        
Investigations- early*        
Plasma glucose 
(mmol/L) 
3569 26.5 (9.1) 3198 26.9 (8.9) 371 23.1 (10.8) 1x10-15 
HbA1c (%) 3541 10.6 (4.5) 3161 10.7 (4.5) 380 9.9 (5.1) 9x10-8 
DKA (%) 3933 15 (601) 3471 17 (574) 462 6 (27) 6x10-11 
        
Investigations – 
delayed† 
       
High risk HLA (%) 3876 69 (2693) 3419 73 (2486) 457 45 (207) 2x10-30 
C peptide (nmol/mol) 3596 0.35 (0.44) 3184 0.28 (0.23) 412 0.85 (0.98) 3x10-36 
C Peptide <0.2 
(nmol/mol) (%) 
3596 40 (1434) 3184 42 (1337) 412 24 (97) 1x10-13 
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 Research tested  
Autoantibody negative 
Not tested  
Autoantibody negative 
Phenotype N mean (SD) 
or % (N) 
N mean (SD) 
or % (N) 
P value 
* 
Clinical features      
N 227  159   
Sex (% female) 227 37 (85) 159 42 (66) 0.46 
Age at diagnosis (yrs) 227 12.06 (4.47) 159 10.88 (4.57) 0.01 
Parental Diabetes (%) 227 25 (56) 159 15 (24) 0.03 
Polyuria (%) 189 79 (150) 122 87 (106) 0.10 
Polydipsia (%) 186 80 (149) 122 85 (104) 0.29 
Weight loss (%) 178 58 (104) 118 69 (81) 0.09 
BMI (SDS) 178 0.42 (1.96) 118 0.28 (1.85) 0.55 
Acanthosis Nigricans (%)  178 9 (16) 115 8 (9) 0.83 
      
Investigations- early      
Plasma glucose (mmol/L) 186 23.6 (10.2) 121 25.9 (11.2) 0.05 
HbA1c (%) 186 10.3 (5.0) 123 10.3 (5.1) 0.88 
DKA (%) 227 6 (13) 159 8 (13) 0.41 
      
Investigations - delayed      
High risk HLA (%) 226 46 (103) 155 53 (82) 0.18 
C peptide (nmol/mol) 213 0.86 (1.01) 131 0.83 (1.07) 0.08 
 
Supplementary table 2. Comparing the research tested autoantibody negative group with those not 
tested to assess if representative  
Plasma glucose and C-peptide results based on log10 transformation. 
* to correct for the 13 variables analysed a p value of < 0.004 should be considered significantly 
different. 
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 Research tested 
Autoantibody positive 
Not tested 
Autoantibody positive 
Phenotype N mean (SD) 
or % (N) 
N mean (SD) 
or % (N) 
P value 
*  
Clinical features      
N 177  3294   
Sex (% female) 177 49 (87) 3294 45 (1479) 0.28 
Age at diagnosis (yrs) 177 9.54 (4.43) 3294 9.91 (4.39) 0.27 
Parental Diabetes (%) 177 8 (15) 3294 11 (364) 0.32 
Polyuria (%) 156 95 (148) 3077 96 (2956) 0.40 
Polydipsia (%) 156 94 (147) 3069 95 (2930) 0.43 
Weight loss (%) 146 73 (107) 2983 78 (2316) 0.22 
BMI (SDS) 143 -0.17 (1.56) 2877 -0.45 (1.49) 0.03 
Acanthosis Nigricans (%) 154 1 (2) 2982 1 (15) 0.20 
      
Investigations- early      
Plasma glucose (mmol/L) 155 25.3 (7.4) 3043 27.0 (8.9) 0.02 
HbA1c (%) 154 10.5 (4.5) 3007 10.7 (4.5) 0.22 
DKA (%) 177 12 (21) 3294 17 (553) 0.10 
      
Investigations - delayed      
High risk HLA (%) 177 72 (128) 3242 73 (2358) 0.93 
C peptide (nmol/mol) 166 0.34 (0.263) 3018 0.28 (0.231) 4x10-4 
      
Antibodies      
1 antibody +ve 177 23 (40) 3294 19 (618) 0.20 
2 antibody +ve  177 35 (61) 3294 34 (1108) 0.81 
3 antibody +ve 177 31 (54) 3294 34 (1117) 0.37 
4 antibody +ve 177 12 (22) 3294 14 (451) 0.74 
 
Supplementary table 3. Comparing the research tested autoantibody positive group with those not 
tested to assess if representative.   Plasma glucose and C peptide results based on log10 
transformation. * to correct for the 17 variables analysed a p value of < 0.003 should be considered 
significantly different. 
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IAA positive 
n=1205 
31% 
ZnT8A positive 
n=2397 
61% 
IA2A positive 
n=2718 
69% 
Supplementary Figure 1: Breakdown of autoantibody positivity in 3933 individuals tested  
Venn diagram produced using venndiag stata package 
   
   
   
   
GADA positive 
n=2081 
53% 
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 Patients Tested 
Clinically 
Patients Not Tested 
Clinically 
Phenotype N mean (SD) 
or % (N) 
N mean (SD) 
or % (N) 
P 
Clinical features      
N 81  3852   
Sex (% female) 81 49 (40) 3852 45 (1715) 0.43 
Age at diagnosis (yrs) 81 11.8 (4.02) 3852 10.1 (4.44) 3x10-4 
Parental Diabetes (%) 81 54 (44) 3852 12 (456) 1x10-19 
Polyuria (%) 69 54 (37) 3539 95 (3355) 5x10-22 
Polydipsia (%) 69 55 (38) 3528 94 (3325) 1x10-19 
Weight loss (%) 67 31 (21) 3420 76 (2604) 2x10-14 
BMI (SDS) 67 0.78 (1.46) 3311 -0.37 (1.55) 2x10-8 
Acanthosis Nigricans (%) 66 3 (2) 3424 1 (42) 0.20 
      
Investigations- early      
Plasma glucose (mmol/L) 69 17.0 (8.9) 3500 26.7 (9.0) 3x10-13 
HbA1c (%) 76 8.2 (4.8) 3465 10.7 (4.5) 9x10-12 
DKA (%) 81 1 (1) 3852 16 (600) 3x10-5 
      
Investigations – delayed      
4 Autoantibody negative (%) 81 94 (76) 3852 10 (386) 9x10-67 
High risk HLA (%) 81 28 (23) 3795 70 (2670) 2x10-14 
C peptide (nmol/mol) 72 0.85 (0.69) 3524 0.34 (0.43) 2x10-12 
C Peptide < 0.2 (nmol/mol) 
(%) 
72 13 (9) 3524 40 (1425) 5x10-7 
 
Supplementary Table 4. Characteristics of the patients referred for genetic testing (and not referred 
for genetic testing) by clinicians. Plasma glucose and C peptide results based on log10 
transformation.
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Study 
Number 
Gene DNA description* Protein 
Description* 
Predicted Effect No. of 
heterozygotes 
in GnomAD†  
Variant 
Classification‡ 
References Clinician 
requested 
test? 
BDD0024 GCK c.772G>T p.(Gly258Cys) Missense 0/123027 Pathogenic Mantovani (2003) Hum Mutat 22, 338 No 
BDD0068 GCK c.571C>T p.(Arg191Trp) Missense 2/123005 Pathogenic Ellard (2000) Diabetologia 43, 250 Yes 
BDD0377 HNF4A c.47dup p.(Tyr16Ter) Nonsense 0/15464 Pathogenic Novel Yes 
BDD0387 GCK c.1016A>G p.(Glu339Gly) Missense 0/118808 Pathogenic Sagen (2006) Diabetes 55, 1713 Yes 
BDD0422 GCK c.766G>A p.(Glu256Lys) Missense 1/123047 Pathogenic Gidh-Jain (1993) Proc Natl Acad Sci U S A 90, 1932 Yes 
BDD0647 GCK c.704T>C p.(Met235Thr) Missense 0/122988 Pathogenic Gloyn (2003) Hum Mutat 22, 353 Yes 
BDD0664 HNF1A c.872dup p.(Gly292fs) Frameshift 0/132382 Pathogenic Yamagata (1996) Nature 384, 455 Yes 
BDD0665 GCK c.675C>G p.(Ile225Met) Missense 0/123114 Likely Pathogenic Massa (2001) Diabetologia 44, 898 Yes 
BDD0717 HNF1A c.872dup p.(Gly292fs) Frameshift 0/132382 Pathogenic Yamagata (1996) Nature 384, 455 Yes 
BDD0809 HNF4A c.46_49+6delinsG p.(?) Aberrant splicing 0/15464 Pathogenic Novel Yes 
BDD0840 GCK c.766G>A p.(Glu256Lys) Missense 1/123047 Pathogenic Gidh-Jain (1993) Proc Natl Acad Sci U S A 90, 1932 Yes 
BDD0842 GCK c.854G>A p.(Gly285Asp) Missense 0/120800 Likely Pathogenic Novel (1 family in MODY DB) Yes 
BDD0911 GCK c.766G>A p.(Glu256Lys) Missense 1/123047 Pathogenic Gidh-Jain (1993) Proc Natl Acad Sci U S A 90, 1932 Yes 
BDD1002 HNF4A c.956_958dup p.(Leu319dup) In-frame amino 
acid deletion 
0/122264 Pathogenic Pearson (2005) Diabetologia 48, 878 Yes 
BDD1107 HNF1A c.814C>T p.(Arg272Cys) Missense 0/121947 Pathogenic Yoshiuchi (1999) Diabetologia 42, 621 Yes 
BDD1337 GCK c.680-2A>G p.(?) Aberrant splicing 0/122599 Pathogenic Osbak (2009) Hum Mutat 30, 1512 Yes 
BDD1433 GCK c.442T>A p.(Phe148Ile) Missense 0/123131 Likely Pathogenic Osbak (2009) Hum Mutat 30, 1512 Yes 
BDD1470 GCK c.878T>G p.(Ile293Arg) Missense 0/122348 Pathogenic Novel (3 families in MODY DB) Yes 
BDD1515 HNF4A c.956_958dup p.(Leu319dup) In-frame amino 
acid deletion 
0/122264 Pathogenic Pearson (2005) Diabetologia 48, 878 Yes 
BDD1526 GCK c. 704T>C p.(Met235Thr) Missense 0/122988 Pathogenic Gloyn (2003) Hum Mutat 22, 353 Yes 
BDD1557 HNF4A c.1A>G p.(?) Start-loss 0/122240 Pathogenic Novel Yes 
BDD1586 GCK c.623C>T p.(Ala208Val)  Missense 1/123121 Pathogenic Osbak (2009) Hum Mutat 30, 1512 Yes 
BDD1930 GCK c.490C>T p.(Leu164Phe) Missense 0/15478 Likely Pathogenic Nam (2000) Diabetes Res Clin Pract 50, 169 Yes 
BDD2002 GCK c.766G>A p.(Glu256Lys) Missense 1/123047 Pathogenic Gidh-Jain (1993) Proc Natl Acad Sci U S A 90, 1932 Yes 
BDD2035 GCK c.1144T>C p.(Cys382Arg) Missense 0/115895 Pathogenic Osbak (2009) Hum Mutat 30, 1512 Yes 
BDD2161 GCK c.680-2A>G p.(?) Aberrant splicing 0/122599 Pathogenic Osbak (2009) Hum Mutat 30, 1512 No 
BDD2282 HNF1A c.493T>C p.(Trp165Arg) Missense 0/138536 Pathogenic Tatsi (2013) Pediatr Diabetes epub, epub Yes 
BDD2362 GCK c.929T>G p.(Val310Gly) Missense 1/121775 Likely Pathogenic Novel (2 families in MODY DB) Yes 
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BDD2549 HNF4A c.931C>T p.(Arg311Cys)  Missense 0/121920 Pathogenic Yorifuji (2012) Pediatr Diabetes 13, 26 No 
BDD2655 GCK c.869A>G p.(Glu290Gly) Missense 0/121651 Likely Pathogenic Novel No 
BDD2788 HNF1A c.1340C>T p.(Pro447Leu) Missense 0/15467 Pathogenic Yamagata (1996) Nature 384, 455 No 
BDD2801 GCK c.1305dup p.(Ile436fs) Frameshift 0/120231 Pathogenic Novel No 
BDD2844 GCK c.1142T>C p.(Met381Thr) Missense 0/115895 Pathogenic Osbak (2009) Hum Mutat 30, 1512 Yes 
BDD2952 GCK c.162T>G p.(Ser54Arg) Missense 3/123132 Likely Pathogenic Novel (2 families in MODY DB) Yes 
BDD3040 GCK c. 704T>C p.(Met235Thr) Missense 0/122988 Pathogenic Gloyn (2003) Hum Mutat 22, 353 No 
BDD3079 GCK c.766G>A p.(Glu256Lys) Missense 1/123047 Pathogenic Gidh-Jain (1993) Proc Natl Acad Sci U S A 90, 1932 Yes 
BDD3233 GCK c.571C>T p.(Arg191Trp) Missense 2/123005 Pathogenic Ellard (2000) Diabetologia 43, 250 Yes 
BDD3254 GCK c. 704T>C p.(Met235Thr) Missense 0/122988 Pathogenic Gloyn (2003) Hum Mutat 22, 353 Yes 
BDD3490 HNF4A c.47dup p.(Tyr16Ter) Nonsense 0/15464 Pathogenic Novel No 
BDD3591 HNF1A c.160C>T p.(Arg54Ter) Nonsense 0/116545 Pathogenic Lambert (2003) Diabetes Care 26, 333 No 
BDD3640 GCK c.854G>A p.(Gly285Asp) Missense 0/120800 Likely Pathogenic Novel (1 family in MODY DB) No 
BDD3791 HNF1A c.25C>T p.(Gln9Ter) Nonsense 0/121466 Pathogenic Novel Yes 
BDD3798 HNF1A c.431T>C p.(Leu144Pro) Missense 0/123112 Pathogenic Colclough (2013) Hum Mutat 34, 669 No 
BDD3961 HNF1A c.366C>G p.(Tyr122Ter) Nonsense 0/123098 Pathogenic Novel Yes 
BDD3973 GCK c.1167_1168dupCA p.(Ile390fs) Frameshift 0/112573 Pathogenic Novel Yes 
BDD3980 HNF1A c.872dup p.(Gly292fs) Frameshift 0/132382 Pathogenic Yamagata (1996) Nature 384, 455 No 
Supplementary table 5: Pathogenic MODY gene variants identified in the cohort 
*Variants described according to Human Genome Variation Society (HGVS) nomenclature guidelines v15.11 and using the reference sequences NM_000162.3 for 
GCK, NM_000545.6 for HNF1A, NM_175914.4 for HNF4A and NM_000458.3 for HNF1B. 
†GnomAD data is number of heterozygous individuals identified out of the total number of individuals with genotype quality (GQ) >= 20 and depth (DP) >= 10 over a 
10bp window containing the variant.  GnomAD data accessed on 03/11/2017. 
‡Variants classified according to the ACGS and ACMG best practice guidelines for variant interpretation 
(http://www.acgs.uk.com/media/1092626/uk_practice_guidelines_for_variant_classification_2017.pdf and 
https://www.acmg.net/docs/Standards_Guidelines_for_the_Interpretation_of_Sequence_Variants.pdf). 
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Supplementary Figure 2 (REPLACE WITH NEW VERSION). Fasting plasma glucose in both known 
MODY patients (both GCK and HNF1A/HNF4A)  and those without known MODY (antibody negative 
and antibody positive)..  
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Supplementary Table 6: Differences in autoantibody negative patients with or without MODY. 
This table consist of only the 303 antibody negative patients who were sequenced for MODY. Plasma 
glucose and C peptide results based on log10 transformation. 
~ local testing with results 0-24 hours  
# testing at reference laboratory, results within 14-90 days 
  
 MODY  Not  MODY  
Phenotype N mean (SD) 
or % (N) 
N mean (SD) 
or % (N) 
P 
Clinical features 
     
N 46  257   
Sex (% female)  46 54 (25) 257 38 (98) 0.05 
Age at diagnosis (yrs) 46 12.1 (4.39) 257 12.0 (4.39) 0.84 
Parental Diabetes (%) 46 63 (29) 257 27 (68) 4x10-6 
Polyuria (%) 38 34 (13) 215 79 (169) 1x10-7 
Polydipsia (%) 38 34 (13) 212 80 (169) 6x10-8 
Weight loss (%) 38 16 (6) 202 57 (115) 2x10-6 
BMI (SDS) 37 0.54 (1.21) 203 0.50 (1.92) 0.85 
Acanthosis Nigricans (%) 37 0 (0.00) 202 9 (18) 0.08 
      
Investigations- early~ 
     
Plasma glucose (mmol/L) 41 11.7 (4.13) 209 23.7 (10.0) 7x10-18 
HbA1c (%) 46 7.0 (3.7) 211 10.2 (5.0) 4x10-19 
DKA (%) 46 0 (0) 257 5 (14) 0.14 
      
Investigations – delayed# 
     
High risk HLA (%) 46 20 (9) 256 45 (116) 1x10-3 
C peptide (nmol/mol) 41 0.81 (0.63) 240 0.48 (0.99) 1x10-4 
C Peptide < 0.2 nmol/mol 
(%) 
41 2 (1) 240 23 (54) 1x10-3 
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 GCK MODY Not known MODY 
Phenotype N mean (SD) 
or % (N) 
N mean (SD) 
or % (N) 
P  
Clinical features      
N 29  3887   
Sex (% female) 29 41 (12) 3887 45 (1730) 0.85 
Age at diagnosis (yrs) 29 11.0 (4.8) 3887 10.1 (4.4) 0.25 
Parental Diabetes (%) 29 62 (18) 3887 12 (471) 4x10-10 
Polyuria (%) 23 26 (6) 3570 95 (3379) 4x10-17 
Polydipsia (%) 23 26 (6) 3559 94 (3350) 2x10-16 
Weight loss (%) 23 13 (3) 3449 76 (2619) 4x10-10 
BMI (SDS) 22 0.50 (1.23) 3341 -0.36 (1.55) 4x10-3 
Acanthosis Nigricans (%) 22 0 (0) 3453 1 (44) 1 
      
Investigations- early      
Plasma glucose (mmol/L) 24 9.9 (2.5) 3528 26.7 (9.0) 7x10-16 
HbA1c (%) 29 6.3 (2.5) 3495 10.7 (4.5) 2x10-47 
DKA (%) 29 0 (0) 3887 15 (601) 0.02 
      
Investigations – delayed      
4 Antibody negative (%) 29 100 (29) 3887 11 (416) 2x10-28 
High risk HLA (%) 29 14 (4) 3830 70 (2684) 6x10-10 
C peptide (nmol/mol) 26 0.92 (0.62) 3555 0.34 (0.43) 3x10-8 
C Peptide < 0.2 nmol/mol 
(%) 
26 4 (1) 3555 40 (1433) 1x10-4 
 
Supplementary table 7: GCK-MODY only vs. non-MODY. Plasma glucose and C peptide results based 
on log10 transformation. 
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 HNF1A/HNF4A 
MODY 
Not known MODY 
Phenotype N mean (SD) 
or % (N) 
N mean (SD) 
or % (N) 
P  
Clinical features      
N 17  3887   
Sex (% female)  17 76 (13) 3887 45 (1730) 0.01 
Age at diagnosis (yrs) 17 13.8 (3.2) 3887 10.1 (4.4) 2x10-4 
Parental Diabetes (%) 17 65 (11) 3887 12 (471) 6x10-7 
Polyuria (%) 15 47 (7) 3570 95 (3379) 4x10-7 
Polydipsia (%) 15 47 (7) 3559 94 (3350) 7x10-7 
Weight loss (%) 15 0.2 (3) 3449 76 (2619) 9x10-6 
BMI (SDS) 15 0.61 (1.2) 3341 -0.36 (1.6) 0.009 
Acanthosis Nigricans (%) 15 0 (0) 3453 1 (44) 1 
      
Investigations- early      
Plasma glucose (mmol/L) 17 14.2 (4.8) 3528 26.7 (9.0) 7x10-7 
HbA1c (%) 17 8.3 (2.4) 3495 10.7 (4.5) 1x10-4 
DKA (%) 17 0 (0) 3887 15 (601) 0.09 
      
Investigations – delayed      
4 Antibody negative (%) 17 100 (17) 3887 11 (416) 4x10-17 
High risk HLA (%) 17 29 (5) 3830 70 (2684) 7x10-4 
C peptide (nmol/mol) 15 1.10 (0.63) 3555 0.34 (0.43) 6x10-8 
C Peptide < 0.2 nmol/mo) 
(%) 
15 0 (0) 3555 40 (1433) 7x10-4 
 
Supplementary table 8: HNF1A/HNF4A MODY vs. Not known MODY.  
Plasma glucose and C peptide results based on log10 transformation. 
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 GCK MODY HNF1A/4A MODY 
Phenotype N mean (SD) 
or % (N) 
N mean (SD) 
or % (N) 
P  
Clinical features      
N 29  17   
Sex (% female) 29 41 (12) 17 76 (13) 0.03 
Age at diagnosis (yrs) 29 11.0 (4.8) 17 13.8 (3.2) 0.04 
Parental Diabetes (%) 29 62 (18) 17 65 (11) 1.00 
Polyuria (%) 23 26 (6) 15 47 (7) 0.30 
Polydipsia (%) 23 26 (6) 15 47 (7) 0.30 
Weight loss (%) 23 13 (3) 15 20 (3) 0.66 
BMI (SDS) 22 0.50 (1.23) 15 0.61 (1.2) 0.79 
Acanthosis Nigricans (%) 22 0 (0) 15 0 (0) 1.00 
      
Investigations- early      
Plasma glucose (mmol/L) 24 9.9 (2.5) 17 14.2 (4.8) 6x10-4 
HbA1c (%) 29 6.3 (2.5) 17 8.3 (2.4) 0.01 
DKA (%) 29 0 (0) 17 0 (0) 1.00 
      
Investigations – delayed      
4 Antibody negative (%) 29 100 (29) 17 100 (17) 1.00 
High risk HLA (%) 29 14 (4) 17 29 (5) 0.26 
C peptide (nmol/mol) 26 0.92 (0.62) 15 1.10 (0.63) 0.38 
C Peptide < 0.2 (nmol/mol) 
(%) 
26 4 (1) 15 0 (0) 1.00 
 
Supplementary table 9: HNF1A/HNF4A MODY vs. GCK MODY. Plasma glucose and C peptide results 
based on log10 transformation. 
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Criteria Total number 
autoantibody 
negative 
Total number of 
individuals tested for 
MODY 
Number (%) of the 46 
MODY patients detected 
All 380 257 46 (100%) 
HbA1c<7.5% 
(58mmol/mol) 
100 (26%) 73 (28%) 36 (78%) 
Parent affected 120 (32%) 96 (37%) 29 (63%) 
HbA1c < 7.5% 
(58mmol/mol) or 
parent affected 
174 (46%) 131 (51%) 44 (96%) 
HbA1c < 7.5% 
(58mmol/mol) and 
parent affected 
46 (12%) 38 (15%) 21 (46%) 
    
Supplementary Table 10: Effectiveness of HbA1c and family history on identifying MODY in 
autoantibody negative individuals.   
*Note this table only includes the patients who had HbA1c at diagnosis data.  This was available on 
380 of 462 patients that were negative for all 4 antibodies and 257 of 303 patients that were 
negative for all 4 antibodies and were sequenced. Parental history was available on all subjects. The 
percentages shown in are of the patients in whom HbA1c was available 
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No Study 
Number 
Sex Age Initial diagnosis Initial treatment Clinical / Research 
Diagnostic Test 
Current Treatment 
 
HbA1c 
mmol/mol 
Follow up 
years 
1 BDD0024 M 5.4 Unclassified None Clinical    GCK None 42 8 
2 BDD0068 M 11.1 Unclassified None Clinical    GCK None 47 7.5 
3 BDD0377 M 15 susp MODY Insulin Clinical    GCK None 40 3 
4 BDD0387 F 15.6 Type 2 Diet Clinical    GCK None 47 9.5 
5 BDD0422 M 16.1 susp MODY Diet Clinical    GCK None 51 3 
6 BDD0647 M 16.4 susp MODY Diet Clinical    GCK None 38 4.5 
7 BDD0664 F 16 susp MODY Diet Clinical    GCK None 42 2 
8 BDD0665 F 13.7 susp MODY Diet Clinical    GCK None 34 2 
9 BDD0717 M 6.5 susp MODY Diet Clinical    GCK None 51 4 
10 BDD0809 F 16.2 susp MODY Diet Clinical    GCK None 42 2 
11 BDD0840 F 5.8 susp MODY Diet Clinical    GCK None 47 10 
12 BDD0842 F 6.6 Type 1 Diet Clinical    GCK None 46 8 
13 BDD0911 M 9.9 susp MODY Insulin Clinical    GCK None 46 10 
14 BDD1002 F 17 Type 2 Metformin Clinical    GCK None 51 1.5 
15 BDD1107 M 7.8 susp MODY Diet Clinical    GCK None 47 8.5 
16 BDD1337 M 5.5 susp MODY Diet Clinical    GCK None 41 9 
17 BDD1433 F 14.4 susp MODY Insulin Clinical    GCK None 40 8 
 15
18 BDD1470 F 11.8 susp MODY Diet Clinical    GCK None 42 6 
19 BDD1515 M 16.9 susp MODY None Clinical    GCK None 47 0 
20 BDD1526 M 15 susp MODY Diet Clinical    GCK None 48 0 
21 BDD1557 M 13.9 Type 1 Insulin Clinical    GCK None 44 2 
22 BDD1586 F 3.7 susp MODY None Clinical    GCK None 44 6.5 
23 BDD1930 M 4.9 Type 1 Insulin Clinical    GCK None 48 1 
24 BDD2002 F 11.5 Type 1 Insulin Clinical   HNF1A Sulphonylurea+Insulin* 47 6.5 
25 BDD2035 F 15.5 Type 2 Metformin Clinical   HNF1A Sulphonylurea 36 5 
26 BDD2161 F 15.5 susp MODY Insulin Clinical   HNF1A None 45 8 
27 BDD2282 F 11 Type 2 Diet Clinical   HNF1A Sulphonylurea 59 9.5 
28 BDD2362 M 13.9 susp MODY Insulin Clinical   HNF1A None 40 11 
29 BDD2549 M 7.9 susp MODY None Clinical   HNF1A Sulphonylurea 68 10 
30 BDD2655 F 15.1 Type 1 Insulin Clinical   HNF4A None 52 10 
31 BDD2788 F 7.2 susp.MODY Diet Clinical   HNF4A Sulphonylurea 55 10 
32 BDD2801 F 11.8 susp MODY Insulin Clinical   HNF4A Insulin** 72 4.5 
33 BDD2844 F 15.4 Type 1 Insulin Clinical   HNF4A Insulin*** 60 9 
34 BDD2952 M 16.5 Type 1 Insulin Clinical   HNF4A Insulin**** 67 7.5 
35 BDD3040 M 11 unclass. Diet Research  GCK None 46 7 
36 BDD3079 M 15.5 Type 1 Diet Research  GCK None 36 2.5 
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Supplementary table 10:  Initial and present treatment  
Age = Initial diagnosis of diabetes, susp = suspected, HbA1c after molecular genetic diagnosis 
*Patient chose to stay on insulin in addition to sulphonylurea, **reported worse control on sulphonylurea so recommended insulin, *** has not tried Sulphonylurea,  ****tried 
glibenclamide, but chose to continue Insulin  
  
37 BDD3233 F 2.8 Type 1 Insulin Research  GCK None 46 7 
38 BDD3254 F 4 Type 1 Insulin Research  GCK None 53 7 
39 BDD3490 M 13.2 Type 2 Metformin Research  GCK None 43 5 
40 BDD3591 M 9.7 susp MODY None Research  GCK None 42 11 
41 BDD3640 F 10.8 susp MODY None Research HNF1A None 49 6.5 
42 BDD3791 F 15.8 Type 1 Insulin. Research HNF1A Sulphonylurea+Januvia 40 9 
43 BDD3798 F 17.1 Type 2 Insulin+Metformin Research HNF1A Sulphonylurea 56 1 
44 BDD3961 M 15.7 Type 1 Insulin Research HNF1A Sulphonylurea 69 2.5 
45 BDD3973 F 16.9 Type 2 Diet Research HNF4A None 33 1 
46 BDD3980 F 17 Type 1 Insulin Research HNF4A Sulphonylurea 50 6.5 
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 Antibody Negative 
Patients Clinically 
Tested 
Antibody Negative 
Patients Not 
Clinically Tested 
Phenotype N mean (SD) 
or % (N) 
N mean (SD) 
or % (N) 
P 
Clinical features      
N 76  386   
Sex (% female) 76 50 (38) 386 39 (151) 0.10 
Age at diagnosis (yrs) 76 11.7 (4.1) 386 11.6 (4.6) 0.75 
Parental Diabetes (%) 76 54 (41) 386 21 (80) 2x10-8 
Polyuria (%) 64 50 (32) 311 82 (256) 2x10-7 
Polydipsia (%) 64 52 (33) 308 82 (253) 9x10-7 
Weight loss (%) 62 27 (17) 296 63 (185) 5x10-7 
BMI SDS  62 0.75 (1.38) 296 0.37 (1.91) 0.07 
Acanthosis Nigricans (%) 61 3 (2) 293 9 (25) 0.19 
      
Investigations - early      
Plasma glucose (mmol/L) 64 16.3 (8.5) 307 24.6 (10.7) 1x10-9 
HbA1c (%) 71 8.1 (4.8) 309 10.3 (5.0) 1x10-8 
DKA (%) 76 1 (1) 386 7 (26) 0.10 
      
Investigations – delayed      
High risk HLA (%) 76 29 (22) 381 45 (185) 0.002 
C peptide (nmol/mol) 68 0.89 (0.69) 344 0.85 (1.03) 0.02 
C Peptide < 0.2 (nmol/mol) 68 12 (8) 344 26 (89) 0.012 
 
Supplementary Table 11. Characteristics of the patients referred for genetic testing and antibody 
negative patients not referred for genetic testing by clinicians. Plasma glucose and C peptide results 
based on log10 transformation. 
 
 
 
 
